{"downloaded": true, "htmlmade": false, "full": {"id": "29724198", "source": "MED", "pmid": "29724198", "pmcid": "PMC5934787", "fullTextIdList": {"fullTextId": "PMC5934787"}, "doi": "10.1186/s12933-018-0709-9", "title": "The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial.", "authorString": "Dore FJ, Domingues CC, Ahmadi N, Kundu N, Kropotova Y, Houston S, Rouphael C, Mammadova A, Witkin L, Khiyami A, Amdur RL, Sen S.", "authorList": {"author": [{"fullName": "Dore FJ", "firstName": "Fiona J", "lastName": "Dore", "initials": "FJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "The GW Medical Faculty Associates, Washington, DC, USA."}}}, {"fullName": "Domingues CC", "firstName": "Cleyton C", "lastName": "Domingues", "initials": "CC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medicine, The George Washington University, 2300 Eye Street, Washington, DC, 20037, USA."}}}, {"fullName": "Ahmadi N", "firstName": "Neeki", "lastName": "Ahmadi", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medicine, The George Washington University, 2300 Eye Street, Washington, DC, 20037, USA."}}}, {"fullName": "Kundu N", "firstName": "Nabanita", "lastName": "Kundu", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medicine, The George Washington University, 2300 Eye Street, Washington, DC, 20037, USA."}}}, {"fullName": "Kropotova Y", "firstName": "Yana", "lastName": "Kropotova", "initials": "Y", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medicine, The George Washington University, 2300 Eye Street, Washington, DC, 20037, USA."}}}, {"fullName": "Houston S", "firstName": "Sara", "lastName": "Houston", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medicine, The George Washington University, 2300 Eye Street, Washington, DC, 20037, USA."}}}, {"fullName": "Rouphael C", "firstName": "Carol", "lastName": "Rouphael", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Medicine, The George Washington University, 2300 Eye Street, Washington, DC, 20037, USA."}, {"affiliation": "Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA."}]}}, {"fullName": "Mammadova A", "firstName": "Aytan", "lastName": "Mammadova", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "The GW Medical Faculty Associates, Washington, DC, USA."}, {"affiliation": "Richmond University Medical Center, Staten Island, NY, USA."}]}}, {"fullName": "Witkin L", "firstName": "Linda", "lastName": "Witkin", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "The GW Medical Faculty Associates, Washington, DC, USA."}}}, {"fullName": "Khiyami A", "firstName": "Anamil", "lastName": "Khiyami", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "The GW Medical Faculty Associates, Washington, DC, USA."}, {"affiliation": "Princess Nora Bint Abdul Rahman University, Riyadh, Saudi Arabia."}, {"affiliation": "Weill Cornell Medicine/New York7-Presbyterian, New York, USA."}]}}, {"fullName": "Amdur RL", "firstName": "Richard L", "lastName": "Amdur", "initials": "RL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "The GW Medical Faculty Associates, Washington, DC, USA."}}}, {"fullName": "Sen S", "firstName": "Sabyasachi", "lastName": "Sen", "initials": "S", "authorId": {"@type": "ORCID", "#text": "0000-0002-3675-9129"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "The GW Medical Faculty Associates, Washington, DC, USA. ssen1@gwu.edu."}, {"affiliation": "Department of Medicine, The George Washington University, 2300 Eye Street, Washington, DC, 20037, USA. ssen1@gwu.edu."}]}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0002-3675-9129"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "1", "volume": "17", "journalIssueId": "2677883", "dateOfPublication": "2018 May", "monthOfPublication": "5", "yearOfPublication": "2018", "printPublicationDate": "2018-05-01", "journal": {"title": "Cardiovascular diabetology", "ISOAbbreviation": "Cardiovasc Diabetol", "medlineAbbreviation": "Cardiovasc Diabetol", "NLMid": "101147637", "ISSN": "1475-2840", "ESSN": "1475-2840"}}, "pubYear": "2018", "pageInfo": "65", "abstractText": "AIMS:Type 2 diabetes is associated with endothelial dysfunction leading to cardiovascular disease. CD34+ endothelial Progenitor Cells (EPCs) are responsible for endothelial repair and neo-angiogenesis and can be used as a cardiovascular disease risk biomarker. This study investigated whether the addition of saxagliptin, a DPP-IV inhibitor, to metformin, may reduce cardiovascular disease risk in addition to improving glycemic control in Type 2 diabetes patients. METHODS:In 12\u00a0week, double-blind, randomized placebo-controlled trial, 42 subjects already taking metformin 1-2 grams/day were randomized to placebo or saxagliptin 5\u00a0mg. Subjects aged 40-70\u00a0years with diabetes for <\u200910\u00a0years, with no known cardiovascular disease, BMI 25-39.9, HbA1C 6-9% were included. We evaluated EPCs number, function, surface markers and gene expression, in addition to arterial stiffness, blood biochemistries, resting energy expenditure, and body composition parameters. A mixed model regression to examine saxagliptin vs placebo, accounting for within-subject autocorrelation, was done with SAS (p\u2009<\u20090.05). RESULTS:Although there was no significant increase in CD34+ cell number, CD31+ cells percentage increased. Saxagliptin increased migration (in response to SDF1\u03b1) with a trend of higher colony formation count. MNCs cytometry showed higher percentage of CXCR4 double positivity for both CD34 and CD31 positive cells, indicating a functional improvement. Gene expression analysis showed an upregulation in CD34+ cells for antioxidant SOD1 (p\u2009<\u20090.05) and a downregulation in CD34- cells for IL-6 (p\u2009<\u20090.01). For arterial stiffness, both augmentation index and systolic blood pressure measures went down in saxagliptin subjects (p\u2009<\u20090.05). CONCLUSION:Saxagliptin, in combination with metformin, can help improve endothelial dysfunction in early diabetes before macrovascular complications appear. Trial registration Trial is registered under clinicaltrials.gov, NCT02024477.", "affiliation": "The GW Medical Faculty Associates, Washington, DC, USA.", "publicationStatus": "epublish", "language": "eng", "pubModel": "Electronic", "pubTypeList": {"pubType": ["Research Support, Non-U.S. Gov't", "research-article", "Randomized Controlled Trial", "Journal Article", "Clinical Trial, Phase IV"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Endothelium, Vascular", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PP", "qualifierName": "physiopathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Diabetes Mellitus, Type 2", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "N"}, {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "PP", "qualifierName": "physiopathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Metformin", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Adamantane", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "AA", "qualifierName": "analogs & derivatives", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Dipeptides", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antigens, CD34", "meshQualifierList": {"meshQualifier": {"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Hypoglycemic Agents", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Drug Therapy, Combination"}, {"majorTopic_YN": "N", "descriptorName": "Double-Blind Method"}, {"majorTopic_YN": "N", "descriptorName": "Drug Synergism"}, {"majorTopic_YN": "N", "descriptorName": "Time Factors"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "District of Columbia"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Dipeptidyl-Peptidase IV Inhibitors", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Vascular Stiffness", "meshQualifierList": {"meshQualifier": {"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Arterial Pressure", "meshQualifierList": {"meshQualifier": {"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Endothelial Progenitor Cells", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Biomarkers", "meshQualifierList": {"meshQualifier": {"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "N"}}}]}, "keywordList": {"keyword": ["Diabetes", "endothelial progenitor cells", "Arterial stiffness", "Saxagliptin", "Dpp-4 Inhibitor"]}, "chemicalList": {"chemical": [{"name": "Hypoglycemic Agents", "registryNumber": "0"}, {"name": "Dipeptides", "registryNumber": "0"}, {"name": "Antigens, CD34", "registryNumber": "0"}, {"name": "Dipeptidyl-Peptidase IV Inhibitors", "registryNumber": "0"}, {"name": "saxagliptin", "registryNumber": "9GB927LAJW"}, {"name": "Metformin", "registryNumber": "9100L32L2N"}, {"name": "Adamantane", "registryNumber": "PJY633525U"}, {"name": "Biomarkers", "registryNumber": "0"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1186/s12933-018-0709-9"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5934787"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5934787?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "10", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-01-28", "dateOfCreation": "2018-05-05", "firstIndexDate": "2018-05-05", "fullTextReceivedDate": "2020-07-12", "dateOfRevision": "2019-01-28", "electronicPublicationDate": "2018-05-03", "firstPublicationDate": "2018-05-03"}, "htmllinks": "https://europepmc.org/articles/PMC5934787", "abstract": "AIMS:Type 2 diabetes is associated with endothelial dysfunction leading to cardiovascular disease. CD34+ endothelial Progenitor Cells (EPCs) are responsible for endothelial repair and neo-angiogenesis and can be used as a cardiovascular disease risk biomarker. This study investigated whether the addition of saxagliptin, a DPP-IV inhibitor, to metformin, may reduce cardiovascular disease risk in addition to improving glycemic control in Type 2 diabetes patients. METHODS:In 12\u00a0week, double-blind, randomized placebo-controlled trial, 42 subjects already taking metformin 1-2 grams/day were randomized to placebo or saxagliptin 5\u00a0mg. Subjects aged 40-70\u00a0years with diabetes for <\u200910\u00a0years, with no known cardiovascular disease, BMI 25-39.9, HbA1C 6-9% were included. We evaluated EPCs number, function, surface markers and gene expression, in addition to arterial stiffness, blood biochemistries, resting energy expenditure, and body composition parameters. A mixed model regression to examine saxagliptin vs placebo, accounting for within-subject autocorrelation, was done with SAS (p\u2009<\u20090.05). RESULTS:Although there was no significant increase in CD34+ cell number, CD31+ cells percentage increased. Saxagliptin increased migration (in response to SDF1\u03b1) with a trend of higher colony formation count. MNCs cytometry showed higher percentage of CXCR4 double positivity for both CD34 and CD31 positive cells, indicating a functional improvement. Gene expression analysis showed an upregulation in CD34+ cells for antioxidant SOD1 (p\u2009<\u20090.05) and a downregulation in CD34- cells for IL-6 (p\u2009<\u20090.01). For arterial stiffness, both augmentation index and systolic blood pressure measures went down in saxagliptin subjects (p\u2009<\u20090.05). CONCLUSION:Saxagliptin, in combination with metformin, can help improve endothelial dysfunction in early diabetes before macrovascular complications appear. Trial registration Trial is registered under clinicaltrials.gov, NCT02024477.", "Keywords": ["Diabetes", "endothelial progenitor cells", "Arterial stiffness", "Saxagliptin", "Dpp-4 Inhibitor"], "pdflinks": "https://europepmc.org/articles/PMC5934787?pdf=render", "journaltitle": "Cardiovascular diabetology", "authorinfo": ["Dore FJ", "Domingues CC", "Ahmadi N", "Kundu N", "Kropotova Y", "Houston S", "Rouphael C", "Mammadova A", "Witkin L", "Khiyami A", "Amdur RL", "Sen S"], "title": "The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial."}